198 related articles for article (PubMed ID: 27178307)
1. Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment.
Przewratil P; Kobos J; Wnęk A; Szemraj J; Wyrzykowski D; Chrzanowska B; Andrzejewska E; Taran K
Immunol Lett; 2016 Jul; 175():44-9. PubMed ID: 27178307
[TBL] [Abstract][Full Text] [Related]
2. Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.
Zhu L; Xie J; Liu Z; Huang Z; Huang M; Yin H; Qi W; Yang Z; Zhou T; Gao G; Zhang J; Yang X
Cancer Sci; 2018 Jun; 109(6):1981-1994. PubMed ID: 29664206
[TBL] [Abstract][Full Text] [Related]
3. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.
Pan WK; Li P; Guo ZT; Huang Q; Gao Y
Pediatr Blood Cancer; 2015 Aug; 62(8):1414-20. PubMed ID: 25728347
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?
Babiak-Choroszczak L; Giżewska-Kacprzak K; Gawrych E; Fischer K; Walecka A; Puchalska-Niedbał L; Rajewska-Majchrzak J; Bagłaj M
Adv Clin Exp Med; 2018 May; 27(5):703-710. PubMed ID: 29790692
[TBL] [Abstract][Full Text] [Related]
5. Tissue and serum mRNA profile of MMPs-2/9 as a potential novel biomarker for the most individual approach in infantile hemangiomas and cancer disease.
Taran K; Wnęk A; Kobos J; Andrzejewska E; Przewratil P
Immunobiology; 2017 Nov; 222(11):1035-1042. PubMed ID: 28601470
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes.
Park M; Jung HL; Shim YJ; Kim HS; Yoon HS; Park SK; Cheuh HW; Lee MJ; Lee JM; Park ES; Lee JH; Lim YJ; Choi YB
Pediatr Res; 2020 Nov; 88(5):749-755. PubMed ID: 32311699
[TBL] [Abstract][Full Text] [Related]
7. Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy.
Chen XD; Ma G; Huang JL; Chen H; Jin YB; Ye XX; Hu XJ; Lin XX
Pediatr Dermatol; 2013; 30(5):549-53. PubMed ID: 23909679
[TBL] [Abstract][Full Text] [Related]
8. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas.
Baumgarten P; Brokinkel B; Zinke J; Zachskorn C; Ebel H; Albert FK; Stummer W; Plate KH; Harter PN; Hasselblatt M; Mittelbronn M
Histol Histopathol; 2013 Sep; 28(9):1157-66. PubMed ID: 23475388
[TBL] [Abstract][Full Text] [Related]
9. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.
Kopparapu PK; Boorjian SA; Robinson BD; Downes M; Gudas LJ; Mongan NP; Persson JL
Anticancer Res; 2013 Jun; 33(6):2381-90. PubMed ID: 23749886
[TBL] [Abstract][Full Text] [Related]
10. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.
Jinnin M; Medici D; Park L; Limaye N; Liu Y; Boscolo E; Bischoff J; Vikkula M; Boye E; Olsen BR
Nat Med; 2008 Nov; 14(11):1236-46. PubMed ID: 18931684
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol.
Şen HS; Yalçın B; Canpınar H; Ocak S; Akyüz C
Turk J Pediatr; 2020; 62(6):979-985. PubMed ID: 33372436
[TBL] [Abstract][Full Text] [Related]
12. Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment.
Wnęk A; Andrzejewska E; Kobos J; Taran K; Przewratil P
Immunol Lett; 2017 May; 185():27-31. PubMed ID: 28279700
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma.
Makkeyah SM; Elseedawy ME; Abdel-Kader HM; Mokhtar GM; Ragab IA
Pediatr Hematol Oncol; 2022 Apr; 39(3):215-224. PubMed ID: 34477031
[TBL] [Abstract][Full Text] [Related]
14. Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell.
Zhang L; Mai HM; Zheng J; Zheng JW; Wang YA; Qin ZP; Li KL
Int J Clin Exp Pathol; 2014; 7(1):48-55. PubMed ID: 24427325
[TBL] [Abstract][Full Text] [Related]
15. Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor.
Ozeki M; Nozawa A; Hori T; Kanda K; Kimura T; Kawamoto N; Fukao T
Pediatr Int; 2016 Nov; 58(11):1130-1135. PubMed ID: 26991797
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma.
Aydin Köker S; Kömüroğlu AU; Köksoy AY; Şiraz ÜG; Tekin E; Köker A
Arch Pediatr; 2021 May; 28(4):296-300. PubMed ID: 33715934
[TBL] [Abstract][Full Text] [Related]
17. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A.
Chim H; Armijo BS; Miller E; Gliniak C; Serret MA; Gosain AK
Ann Surg; 2012 Jul; 256(1):146-56. PubMed ID: 22580939
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia.
Gebhardt M; Mentlein R; Schaudig U; Pufe T; Recker K; Nölle B; Al-Samir K; Geerling G; Paulsen FP
Ophthalmology; 2005 Jun; 112(6):1023-30. PubMed ID: 15885787
[TBL] [Abstract][Full Text] [Related]
19. VEGF receptor heterodimers and homodimers are differentially expressed in neuronal and endothelial cell types.
Sarkar J; Luo Y; Zhou Q; Ivakhnitskaia E; Lara D; Katz E; Sun MG; Guaiquil V; Rosenblatt M
PLoS One; 2022; 17(7):e0269818. PubMed ID: 35862373
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
